These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32794567)

  • 1. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
    Dubinsky MC; DiBonaventura M; Fan H; Bushmakin AG; Cappelleri JC; Maller E; Thorpe AJ; Salese L; Panés J
    Inflamm Bowel Dis; 2021 Jun; 27(7):983-993. PubMed ID: 32794567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
    Dubinsky MC; Armuzzi A; Gecse KB; Ullman T; Bushmakin AG; DiBonaventura M; Cappelleri JC; Connelly SB; Woolcott JC; Salese L
    Dig Dis; 2023; 41(4):604-614. PubMed ID: 36603566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
    Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
    J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
    Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
    Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
    Hanauer S; Panaccione R; Danese S; Cheifetz A; Reinisch W; Higgins PDR; Woodworth DA; Zhang H; Friedman GS; Lawendy N; Quirk D; Nduaka CI; Su C
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):139-147. PubMed ID: 30012431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
    Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Healey P
    J Crohns Colitis; 2016 Nov; 10(11):1310-1315. PubMed ID: 27194530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
    Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
    Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
    Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
    Motoya S; Watanabe M; Kim HJ; Kim YH; Han DS; Yuasa H; Tabira J; Isogawa N; Arai S; Kawaguchi I; Hibi T
    Intest Res; 2018 Apr; 16(2):233-245. PubMed ID: 29743836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
    Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
    Allegretti JR; Gecse KB; Chiorean MV; Argollo M; Guo X; Lawendy N; Su C; Mundayat R; Paulissen J; Salese L; Irving PM
    J Gastroenterol Hepatol; 2024 Feb; 39(2):264-271. PubMed ID: 37953548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.